Lantheus Holdings (LNTH) Stock Price, Quote & News

Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area wi...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 978 671 8001

Fax: 978 671 8860

Website: www.lantheus.com

Address:

201 Burlington Road, South Building, Bedford, United States

Ilya136 Oct. 25 at 2:05 PM

$LNTH Omg RADX RADX RADX RADX and nothing about LNTH on the fricking Lantheus board.

0 · Reply

RadioIsotope25 Oct. 24 at 2:31 PM

$RADX RAD402 formed between MD anderson and Radiopharm Theranostics will enter the clinic end of year for Prostate Cancer. MD Anderson is the best cancer center in the world. $ATNM $LNTH $CLRB $CATX

1 · Reply

RadioIsotope25 Oct. 23 at 1:39 PM

Lantheus has infused near $20 million past 18 months through stock purchases. asset purchases and business deals in past 18-mos. $RADX $LNTH

0 · Reply

NetworkNewsWire Oct. 23 at 1:19 PM

Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market $IZO.CN $IZOZF $NVDA $BFLY $LNTH $RDNT https://ibn.fm/Rus4S

0 · Reply

RADX_enjoyer Oct. 23 at 3:02 AM

$RADX Brookline Capital Markets maintains Buy rating, reduces price target to $13 due to dilution. Brookline are happy about $LNTH increasing its stake in the company to 14.5%, a longer cash runway into 2027, and positive clinical trial updates including RAD101 (which their price target is based on)

1 · Reply

RadioIsotope25 Oct. 22 at 8:02 PM

This last raise to me says a big player will be knocking at the door to buy Radiopharm Theranostics next year. Maybe Lantheus or Novartis. The RAD101 and RAD202 combo is a no brainer for a company serious about cancer imaging and lutetium 177… RADX ceo came from Novartis so he definitely has the connections to get it done and Lantheus now owns 14.5%.. it’s not uncommon for Lantheus investments to actually shine a light on the company to bigger pharma to spotlight acquisitions. He was COO at AAA and they acquired them for $3.9 billion. $RADX $LNTH $NVS

1 · Reply

Blizzzard Oct. 22 at 2:23 PM

$LNTH

0 · Reply

Blizzzard Oct. 21 at 7:59 PM

$LNTH pump it baby

0 · Reply

Blizzzard Oct. 21 at 7:47 PM

$LNTH this stock is so good at red markets

0 · Reply

CH_Expat Oct. 21 at 2:45 PM

$LNTH @RocketThief Already in or waiting for 50?

1 · Reply

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Oct 23, 2025, 8:30 AM EDT - 2 days ago

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

Oct 15, 2025, 4:35 PM EDT - 9 days ago

LANTHEUS DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Lantheus Holdings Investors to Contact the Firm Before the November 10th Deadline

Oct 14, 2025, 6:07 AM EDT - 11 days ago

Lantheus Holdings: Not An Easy Buy, But The Company Continues To Create Value

Oct 12, 2025, 9:01 AM EDT - 13 days ago

LNTH INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Oct 10, 2025, 9:23 PM EDT - 14 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Oct 6, 2025, 8:45 AM EDT - 19 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Holdings, Inc. Lawsuit - LNTH

Sep 29, 2025, 9:21 AM EDT - 26 days ago

LANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) DEADLINE ALERT Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline

Sep 25, 2025, 8:45 AM EDT - 4 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Lawsuit - LNTH

Sep 24, 2025, 1:00 AM EDT - 4 weeks ago

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

Sep 22, 2025, 5:29 AM EDT - 4 weeks ago

Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH

Sep 21, 2025, 8:47 AM EDT - 4 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus

Sep 19, 2025, 6:33 PM EDT - 5 weeks ago

Did you lose money in LNTH? Shareholders Who Incurred Significant Losses in Lantheus Holdings, Inc. Should Contact Robbins LLP for Information

Sep 10, 2025, 8:00 PM EDT - 6 weeks ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lantheus Holdings, Inc. (LNTH)

Sep 10, 2025, 10:54 AM EDT - 6 weeks ago

LNTH LAWSUIT: Lantheus Holdings Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Sep 9, 2025, 10:09 AM EDT - 6 weeks ago

Lantheus Holdings, Inc. (LNTH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 8:55 PM EDT - 7 weeks ago

LNTH Investors Have Opportunity to Join Lantheus Holdings, Inc. Fraud Investigation with the Schall Law Firm

Aug 6, 2025, 9:09 PM EDT - 2 months ago

Lantheus Holdings, Inc. (LNTH) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 10:09 AM EDT - 2 months ago

Lantheus Holdings: Reassessing The Buy Thesis

Aug 6, 2025, 6:45 AM EDT - 2 months ago

Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent

Jul 22, 2025, 7:00 AM EDT - 3 months ago

Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

Jul 21, 2025, 8:57 AM EDT - 3 months ago

Lantheus Holdings: Forget The Short Term Noise

Jul 16, 2025, 2:45 PM EDT - 3 months ago

Why Is Lantheus Stock Trading Lower On Wednesday?

Jul 1, 2025, 7:28 AM EDT - 4 months ago

Lantheus Seems Worth The (Very Real) Risks

Jun 11, 2025, 4:01 PM EDT - 4 months ago

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Jun 10, 2025, 8:30 AM EDT - 4 months ago

Lantheus to Present at the 2025 Truist Securities MedTech Conference

Jun 2, 2025, 8:00 AM EDT - 5 months ago

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

GEHC

Ilya136 Oct. 25 at 2:05 PM

$LNTH Omg RADX RADX RADX RADX and nothing about LNTH on the fricking Lantheus board.

0 · Reply

RadioIsotope25 Oct. 24 at 2:31 PM

$RADX RAD402 formed between MD anderson and Radiopharm Theranostics will enter the clinic end of year for Prostate Cancer. MD Anderson is the best cancer center in the world. $ATNM $LNTH $CLRB $CATX

1 · Reply

RadioIsotope25 Oct. 23 at 1:39 PM

Lantheus has infused near $20 million past 18 months through stock purchases. asset purchases and business deals in past 18-mos. $RADX $LNTH

0 · Reply

NetworkNewsWire Oct. 23 at 1:19 PM

Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market $IZO.CN $IZOZF $NVDA $BFLY $LNTH $RDNT https://ibn.fm/Rus4S

0 · Reply

RADX_enjoyer Oct. 23 at 3:02 AM

1 · Reply

RadioIsotope25 Oct. 22 at 8:02 PM

1 · Reply

Blizzzard Oct. 22 at 2:23 PM

$LNTH

0 · Reply

Blizzzard Oct. 21 at 7:59 PM

$LNTH pump it baby

0 · Reply

Blizzzard Oct. 21 at 7:47 PM

$LNTH this stock is so good at red markets

0 · Reply

CH_Expat Oct. 21 at 2:45 PM

$LNTH @RocketThief Already in or waiting for 50?

1 · Reply

RadioIsotope25 Oct. 20 at 4:44 PM

$RANI RAD101 – Brain Metastases Imaging (F18) Clinical Phase: Phase 2b - First-in-class PET agent targeting fatty acid synthase (FASN), upregulated in brain metastases. - Imaging data from 3 patients shows strong metabolic activity in suspected relapse zones. - No competitors identified; large addressable market (~300,000 cases/year in US). - Trial design includes PET/MRI concordance and longitudinal follow-up; 12/30 patients dosed. RAD202 – HER2+ Solid Tumor Therapy (Lu177) Clinical Phase: Phase 1 - Nanobody radiotherapeutic targeting HER2+ tumors refractory to Enhertu®. - Favorable safety profile in Cohort 1 (30 mCi); no SAEs observed. - Strong tumor uptake in dosimetry; Cohort 2 (75 mCi) approved. - Differentiation from existing HER2 therapies will depend on post-Enhertu positioning. $CATX $RADX $LNTH

0 · Reply

RadioIsotope25 Oct. 20 at 1:47 PM

$LNTH

0 · Reply

RADX_enjoyer Oct. 20 at 9:55 AM

$RADX ASX listing closed at an equivalent price of ~US$ 5.65. $LNTH bought US$ 5m worth of shares in today's offering (21% of the total raise) at US$ 6 per RADX share, bringing Lantheus' total holding to 14.5% of the company. US Healthcare funds have also participated in the offering via Leerink Partners (healthcare specialised investment bank) and B. Riley Securities. Positive clinical trial updates were released alongside the offering. GLTA

1 · Reply

RadioIsotope25 Oct. 19 at 1:49 PM

$RADX $LNTH investing millions into Radiopharm Theranostics - stock resumes trading on Monday!!! $RANI

0 · Reply

RadioIsotope25 Oct. 19 at 3:45 AM

When this deal closes $LNTH owns 15% of company and has invested $15 million. Inferring a $100,000,000 valuation of their investments. $RADX

0 · Reply

RadioIsotope25 Oct. 18 at 5:32 PM

Lantheus (Nasdaq: $LNTH) increases stake in Radiopharm Theranostics (Nasdaq: $RADX) to 15% backing blockbuster PD-L1 and HER2 and phase 2b imaging agent their Radiotherapeutics have mult-billion dollar revenue upside. Making company a future takeover candidate similar to the multi-billion takeovers of RayzeBio and Fusion. Monday closing oversubscribed private placement Lantheus is the clear global leader in radiopharmaceuticals. $RANI

1 · Reply

RadioIsotope25 Oct. 17 at 5:12 PM

$RADX Lantheus will own roughly 20.56% of Radiopharm Theranostics after the raise Converted to ADRs Pre-Dilution est: 958,20 shs Post Capital Raise: 1,791,541 shs All based off if they raised $24 million at $6.00 per share. $LNTH

3 · Reply

thepalace2007 Oct. 16 at 5:29 PM

$LNTH $70 call option expires 11/21 lots of calls being bought following the money

0 · Reply

HappE Oct. 16 at 4:02 PM

$LNTH this ticker looooves to grab those stop losses. Does it everyday this week...

0 · Reply

TheOutsider_ Oct. 16 at 2:26 PM

$LNTH have a position here

0 · Reply

Blizzzard Oct. 16 at 1:41 PM

$LNTH might want to test 60$ again

0 · Reply

RadioIsotope25 Oct. 16 at 12:47 PM

Radiopharm Announces Strategic Co-Development Partnership + more cash from $LNTH this week… $RADX $RADX https://www.globenewswire.com/news-release/2024/12/30/3002629/0/en/Radiopharm-Announces-Strategic-Co-Development-Partnership-with-Lantheus-for-Australia.html

0 · Reply

Market Cap	3.84B
Revenue (ttm)	1.53B
Net Income (ttm)	312.44M
EPS (ttm)	N/A
PE Ratio	10.50
Forward PE	12.02
Profit Margin	20.37%
Debt to Equity Ratio	0.49

Volume	651,600
Avg Vol	1,539,728
Day's Range	N/A - N/A
Shares Out	67.99M
Stochastic %K	52%
Beta	0.09
Analysts	Strong Sell
Price Target	$83.67